Literature DB >> 2347599

Oligosaccharide Y specific monoclonal antibody and its isotype switch variants.

Z Steplewski1, M Blaszczyk-Thurin, M Lubeck, H Loibner, D Scholz, H Koprowski.   

Abstract

Isotype switch variants of the IgG3 secreting hybridoma BR55-2 were developed with gamma 1, gamma 2b and gamma 2a heavy chains. The variants have the same affinity for antigen and expected affinities for the Fc receptor. The Y antigen defined by MAb BR55-2 has a restricted distribution to breast, colorectal, pancreatic, gastric and small cell lung carcinomas. The MAb BR55-2 also bound to prostatic and laryngeal carcinomas. The BR55-2 defined epitope is expressed by gastrointestinal cancer cell lines as a glycolipid, while the breast carcinoma cells express the same epitope on glycoproteins. These differences may influence tumor cell susceptibility to lysis by MAb BR55-2 and its isotype switch variants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347599     DOI: 10.1089/hyb.1990.9.201

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

1.  Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Authors:  D Scholz; M Lubeck; H Loibner; J McDonald-Smith; Y Kimoto; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.

Authors:  M Dettke; H Loibner
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 3.  Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.

Authors:  Magdalena Thurin
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2021-06

4.  Targeted gene transfer for adenocarcinoma using a combination of tumor-specific antibody and tissue-specific promoter.

Authors:  S Kurane; J C Krauss; E Watari; R Kannagi; A E Chang; S Kudoh
Journal:  Jpn J Cancer Res       Date:  1998-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.